API Product   :    Rasagiline Mesylate
CEP   :    -
WCC   :    ?
Therapeutic Use    :    Anti-Parkinson Drugs
Originator   :    Lundbeck
CAS No.    :    136236-51-6
Trade Name.   :    AZILECT
Molecular Weight   :    171.238 g/mol
Molecular Formula   :    C12H13N
Rasagiline is used alone or with other medications (such as levodopa/carbidopa) to treat symptoms of Parkinson's disease. It can help improve symptoms such as shakiness, stiffness, and difficulty moving. It can also help reduce the amount of "off" time (periods of slow movement or stiffness).
Rasagiline (Azilect, TVP-1012, N-propargyl-1(R)-aminoindan) is an irreversible inhibitor of monoamine oxidase-B used as a monotherapy to treat symptoms in early Parkinson's disease or as an adjunct therapy in more advanced cases. The racemic form of the drug was invented by Aspro Nicholas in the early 1970s. Moussa B.H. Youdim identified it as a potential drug for Parkinson's disease, and working with collaborators at Technion – Israel Institute of Technology in Israel and the drug company, Teva Pharmaceutical, identified the R-isomer as the active form of the drug.